PRNewsWire - Health

USpharma Ltd. Secures Growth Capital Investment by 1315 Capital
Bluesight's Annual Diversion Trends Report Highlights Important Role of Software and Staff Supervision in Controlled Substance Monitoring
NextPlat Issues Interim CEO Update Shareholder Letter
Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)